BRAF p.Val600Glu (V600E) testing to predict response to vemurafenib in malignant melanoma
Record ID 32013000564
English
Authors' recommendations:
In 2012, malignant melanoma was estimated to account for 76,250 new cases and 9,180 deaths in the United States. The overall 5-year survival rate for skin cancer is 90.9%, but median overall survival (OS) drops to 8 to 18 months in patients with metastatic melanoma, the most aggressive form of skin cancer. Until recently, treatment options for metastatic melanoma were limited and relatively ineffective. In 2011, however, the Food and Drug Administration (FDA) approved 2 novel therapies: the kinase inhibitor vemurafenib (proprietary name Zelboraf; Hoffman-LaRoche) and the immune stimulatory agent, ipilimumab (proprietary name Yervoy; Bristol-Myers Squibb). Vemurafenib has been reported to increase OS at 6 months to 84% (compared with 64% in patients treated with dacarbazine) in metastatic melanoma patients who harbor an activating sequence variant in v-raf murine sarcoma viral oncogene homolog B1 (BRAF) gene. The most common BRAF variant is p.Val600Glu (also known as V600E). The cobas 4800 BRAF V600 Mutation Test (Roche Molecular Systems Inc.) has been FDA approved for detection of BRAF p.Val600Glu in metastatic melanoma patients.
Details
Project Status:
Completed
Year Published:
2013
URL for published report:
The report may be purchased from: http://www.hayesinc.com/hayes/crd/?crd=15119
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
United States
MeSH Terms
- Proto-Oncogene Proteins B-raf
- Sulfonamides
- Antineoplastic Agents
Contact
Organisation Name:
HAYES, Inc.
Contact Address:
157 S. Broad Street, Suite 200, Lansdale, PA 19446, USA. Tel: 215 855 0615; Fax: 215 855 5218
Contact Name:
saleinfo@hayesinc.com
Contact Email:
saleinfo@hayesinc.com
Copyright:
2013 Winifred S. Hayes, Inc
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.